Publications by authors named "Ram Babu Sah"
Background: Sorafenib is the standard treatment for patients with advanced HCC with improvement in survival and radiologic progression of the disease. Recently, few studies have advocated the Sorafenib + HAIC combination therapy results in better overall survival and progression-free survival than Sorafenib monotherapy in patients with advanced HCC. Herein, we aim to identify the best possible treatment option among the above two lines of therapy for patients with advanced HCC.
View Article and Find Full Text PDFArticle Synopsis
- - The study assessed the prevalence of obesity hypoventilation syndrome (OHS) among Indian patients with sleep-disordered breathing (SDB), as previous predictors from Western countries were not applicable here.
- - Conducted over a year at a tertiary care institute, the research analyzed 63 SDB patients and found an OHS prevalence of 15.87%, determining predictors such as minimum nocturnal oxygen saturation, forced vital capacity, and BMI.
- - The results indicated that OHS can occur in Indian patients at lower BMI and spirometric values compared to Caucasians, with specific thresholds identified for minimum nocturnal oxygen saturation, FVC, and BMI as indicators of the syndrome.
Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. Acquisition of resistance to osimertinib due to several mechanisms has been reported. We report the first case of an Indian patient with osimertinib resistance, due to C797S mutation.
View Article and Find Full Text PDFhttp://ow.ly/N37030mB8Fi.
View Article and Find Full Text PDF